NewAmsterdam Pharma (NAMS) Financials

NewAmsterdam Pharma (NASDAQ:NAMS) remains a development-stage company with substantial cash resources but continuing operating losses. The latest statements show a sequential improvement in revenue, but research and development spending and cash consumption remain elevated.

• Revenue is showing early sequential growth. Q2 2026 revenue increased to $3.7 million from $3.0 million in Q1 2026, a gain of approximately 22%. However, revenue remained well below the restated $19.1 million reported in Q2 2025.
• The company has a sizable liquidity position. At June 30, 2026, NewAmsterdam held $424.2 million of cash, $209.7 million of short-term investments, and $44.4 million of long-term investments. Including restricted cash, readily available resources totaled approximately $679.6 million.
• Balance-sheet leverage remains limited. Total liabilities were $73.0 million compared with $631.4 million of equity. Current assets of $659.2 million were approximately nine times current liabilities of $73.0 million, providing a substantial liquidity cushion.
• Operating cash burn improved over the longer-term period. Q2 2026 operating cash outflow was $39.2 million, compared with $53.9 million in Q2 2024 and $46.8 million in Q3 2023. The latest burn rate is still significant, but it has generally remained below the heavier outflows seen in some earlier periods.
• Investment income is helping offset some operating losses. Interest and investment income was $5.8 million in Q2 2026, up from $4.9 million in Q2 2024. The company’s large cash and investment balances provide an additional source of non-operating income, although this income can vary with interest rates and portfolio balances.

• Cash declined during the first half of 2026. Cash and equivalents fell from $457.6 million at March 31 to $424.2 million at June 30, while total cash, restricted cash and investments declined from approximately $708.8 million to $679.6 million. The company reported a $32.9 million net decrease in cash during Q2.
• Financing activity has provided recurring support. NewAmsterdam reported approximately $11.0 million of net financing inflows in both Q1 and Q2 2026. The statements classify these amounts as “other financing activities,” so the underlying source and sustainability of the funding should be monitored.
• Non-cash adjustments are material. Q2 2026 included $23.6 million of non-cash adjustments that reduced the difference between the $64.1 million net loss and the $39.2 million operating cash outflow. Investors should distinguish accounting losses from cash burn, while also recognizing that these adjustments do not eliminate the company’s underlying need to fund operations.

• Losses have widened sequentially. Q2 2026 net loss was $64.1 million, or $0.52 per diluted share, compared with a $48.4 million loss, or $0.40 per share, in Q1 2026. The Q2 loss was also substantially larger than the restated $17.4 million loss in Q2 2025.
• Operating expenses continue to exceed revenue by a wide margin. Q2 2026 operating expenses reached $68.6 million, including $41.7 million of research and development expense and $26.9 million of selling, general and administrative expense. Revenue covered only a small portion of these costs, resulting in a $64.9 million operating loss.
• The company continues to consume cash from operations. Operating cash outflow was $39.2 million in Q2 2026 and $30.6 million in Q1 2026. At the first-half 2026 pace, annual operating cash use would be roughly $140 million, before changes in clinical development spending or other working-capital needs.
• Share dilution is a continuing concern. Weighted average diluted shares increased to 119.5 million in Q2 2026 from 112.6 million in Q2 2025 and 90.0 million in Q2 2024. Continued equity issuance or equity-based compensation could reduce existing shareholders’ ownership percentage and increase the amount of future earnings required to achieve positive earnings per share.

Overall, NewAmsterdam’s strong liquidity and low debt provide meaningful financial flexibility for continued development. However, the investment case remains dependent on revenue growth and clinical or commercial progress, because the company is still generating large losses and negative operating cash flow. The restated historical figures also make year-over-year comparisons more difficult, particularly for revenue and net income.